Demyelinating & Inflammatory Disorders:
When the Immune System Attacks the Brain and Spine's Wiring

Not necessarily — not yet. A single episode of neurological dysfunction consistent with demyelination is called a Clinically Isolated Syndrome (CIS). It may be the first presentation of MS, but it requires further investigation — specifically, brain and spine MRI looking for additional lesions — before an MS diagnosis is made. The McDonald Criteria (the international diagnostic standard for MS) require either multiple episodes over time, or evidence of lesions at multiple locations in the brain or spine on MRI. At KIMS, we assess CIS with full MRI, lumbar puncture, and antibody testing to clarify whether the diagnostic criteria for MS are met, whether the episode might be NMO, ADEM, or another condition, and what treatment decision is appropriate.

The time course is the most important distinguishing feature. Stroke produces weakness that begins suddenly — within minutes — and is maximal at onset. GBS produces weakness that builds progressively over days, typically starting in the legs and ascending upward. Both are neurological emergencies requiring immediate assessment. At KIMS Emergency, 040-46324365, both are assessed urgently with CT, MRI, and full neurological examination. If GBS is suspected, nerve conduction studies and CSF analysis are performed urgently.

Not yet — but it can be very effectively controlled. The goal of MS treatment is to prevent relapses, prevent new MRI lesions, and prevent disability accumulation. The high-efficacy disease-modifying therapies available at KIMS — ocrelizumab, natalizumab, cladribine — reduce relapse rates by 60–80% compared to untreated disease. Many MS patients on appropriate therapy live full, active lives without significant disability for decades. The earlier treatment is started after diagnosis, the better the long-term outcome.

MS and NMO can look very similar early. Both cause optic neuritis and spinal cord attacks. But they are distinct diseases with different antibodies, different MRI patterns, and — critically — different treatments. Some medications used in MS (particularly certain high-efficacy treatments like natalizumab and fingolimod) can make NMO worse. The AQP4-IgG blood test distinguishes them. At KIMS, this test is performed on every patient presenting with optic neuritis or transverse myelitis before a diagnostic label is applied.

GBS recovery is slow — often measured in months, not weeks. The time from onset to maximum weakness is typically 2–4 weeks. After that, recovery begins — but in severe cases, particularly where there has been axonal damage rather than purely myelin damage, recovery can take 6–18 months. At KIMS, GBS patients are followed through the recovery period with regular physiotherapy, nerve conduction monitoring, and support for the fatigue and psychological impact that frequently accompany the prolonged recovery. Call 040-44885000 for a follow-up assessment.

Yes — direct neuroimmunology appointments are accepted. Outpatient: 040-44885000 (Mon–Sat). If you have prior MRI films, lumbar puncture results, or antibody reports, please bring them to make the first assessment more efficient. For acute progressive weakness, sudden vision loss, or new severe sensory symptoms, call 040-46324365 immediately.

Initial consultation is typically 30–60 minutes. A first presentation may need MRI brain and spine with gadolinium on the same or next day, a lumbar puncture for CSF analysis, and the antibody panel (AQP4-IgG, MOG-IgG, and others as indicated) — most results are available within 1–2 weeks. The complete diagnostic picture and a treatment plan are usually in place within 2–3 weeks.